New data from the phase 3 help study™ open-label extension evaluating safety and efficacy of takhzyro® (lanadelumab) for hereditary angioedema patients to be presented at european academy of allergy and clinical immunology (eaaci) hybrid congress

Osaka, japan--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced results from two final analyses from the phase 3 help (hereditary angioedema long-term prophylaxis) study™ open-label extension (ole), which evaluated the long-term safety (primary endpoint) and efficacy of takhzyro® (lanadelumab) 300 mg every two weeks for up to 2.5 years. in the first analysis, the mean (min, max) reduction in the attack rate compared to baseline observed in the
TAK Ratings Summary
TAK Quant Ranking